<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6283">
  <stage>Registered</stage>
  <submitdate>26/05/2016</submitdate>
  <approvaldate>26/05/2016</approvaldate>
  <nctid>NCT02787005</nctid>
  <trial_identification>
    <studytitle>Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)</studytitle>
    <scientifictitle>Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-003644-40</secondaryid>
    <secondaryid>3475-199</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Castration-resistant Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Pembrolizumab
Treatment: drugs - Enzalutamide

Experimental: Cohort 1: PD-L1 positive with measurable disease - Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.

Experimental: Cohort 2: PD-L1 negative with measurable disease - Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.

Experimental: Cohort 3: Bone metastases with non-measurable disease - Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.

Experimental: Cohort 4: RECIST 1.1-measureable disease - Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.

Experimental: Cohort 5: Bone metastases only or bone-predominant disease - Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.


Other interventions: Pembrolizumab
Intravenous infusion

Treatment: drugs: Enzalutamide
Oral capsules

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central imaging vendor (Cohorts 1 and 2 combined, Cohort 1, Cohort 2 and Cohort 4)</outcome>
      <timepoint>Up to 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control Rate (DCR) (Cohorts 1 and 2 combined, Cohorts 1, 2, and 3 combined, Cohorts 4 and 5 combined, and by each cohort)</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prostate-specific Antigen (PSA) response rate (Cohorts 1 and 2 combined, Cohorts 1, 2, and 3 combined, Cohorts 4 and 5 combined, and by each cohort)</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants who experience an adverse event (AE) (All cohorts combined and by each cohort)</outcome>
      <timepoint>Up to 27 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants who discontinue study drug due to an AE (All cohorts combined and by each cohort)</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without
             small cell histology. Disease must be either metastatic or locally confined inoperable
             disease that cannot be treated with definitive intent (no chance for a curative
             intervention).

          -  Has supplied tumor tissue from either a newly obtained biopsy or an archival specimen
             from a site not previously irradiated. Participants in Cohorts 1 and 2 with
             visceral/measurable lesions must provide a newly obtained biopsy performed after the
             last line of systemic therapy and an archival specimen, if available. Participants in
             Cohort 3 must provide an archival specimen.

        For Cohorts 1, 2, and 3 only:

          -  Has been treated with:

          -  At least 1 targeted endocrine therapy (defined as second generation antiandrogen
             therapies that include but are not limited to abiraterone acetate with prednisone,
             enzalutamide, and next generation targeted agents such as ARN-509).

          -  At least 1 regimen/line of chemotherapy that contained docetaxel.

          -  No more than 2 chemotherapy regimens.

          -  No more than 3 regimens/lines of the aforementioned treatments (having
             failed/progressed on chemotherapy and targeted endocrine therapy).

        For Cohorts 4 and 5 only:

          -  Failing or showing signs of failure on current pre-chemotherapy enzalutamide treatment
             as defined by Prostate Cancer Working Group 3 PCWG3 guidelines. Participants can have
             failed prior abiraterone treatment before current enzalutamide treatment. Participants
             must have had a clinically meaningful response to enzalutamide treatment.

        For Cohorts 1, 2, 3, 4, and 5:

          -  Has documented prostate cancer progression within 6 months prior to screening, as
             determined by the Investigator, by means of one of the following: 1) PSA progression
             as defined by a minimum of 3 rising PSA levels with an interval of =1 week between
             each assessment where the PSA value at screening should be =2 ng/mL, OR, 2)
             Radiographic disease progression in soft tissue or bone with or without PSA
             progression

          -  Has ongoing androgen deprivation with total serum testosterone &lt;50 ng/dL (&lt;2.0 nM).

          -  Participants receiving bone resorptive therapy (including but not limited to
             bisphosphonate or Receptor activator of nuclear factor kappa-B ligand [RANK-L
             inhibitor]) must have been on stable doses for =4 weeks prior to first dose of study
             drug.

          -  Has a performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale

          -  Males of reproductive potential must agree to use an adequate method of contraception,
             starting with the first dose of study drug through 120 days after the last dose of
             study drug.

          -  Demonstrates adequate organ function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>For Cohorts 1, 2, 3, 4, and 5:

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigation device
             within 4 weeks of the first dose of study drug.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of study
             drug.

          -  Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to the
             first dose of study drug or who has not recovered (i.e., = Grade 1 or at Baseline)
             from AEs due to mAbs administered more than 4 weeks earlier.

          -  Has had prior chemotherapy, targeted small molecule therapy, or external beam
             radiation therapy within 4 weeks prior to the first dose of study drug or who has not
             recovered (i.e., = Grade 1 or at Baseline) from AEs due to a previously administered
             agent.

          -  Has a known additional malignancy that has had progression or has required active
             treatment in the last 3 years. Exceptions include basal cell carcinoma of the skin and
             squamous cell carcinoma of the skin that has undergone potentially curative therapy.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years
             (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs).

          -  Has evidence of interstitial lung disease and/or a history of (non-infectious)
             pneumonitis that required steroids, or current pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Has previously participated in any other pembrolizumab (MK-3475) trial, or received
             prior therapy with an anti-programmed cell death 1 (anti-PD-1, anti-PD ligand 1
             [anti-PD-L1], and anti-PD-L2 [including ipilimumab or any other antibody or drug
             specifically targeting T-cell co-stimulation or checkpoint pathways]).

          -  Has a known history of Human Immunodeficiency Virus (HIV).

          -  Has known active Hepatitis B or Hepatitis C.

          -  Has received a live vaccine within 30 days of planned start of study drug.

        For Cohorts 4 and 5 only:

          -  Has received prior chemotherapy (e.g., docetaxel) for mCPRC.

          -  Has any condition (cardiac, neurologic, absorption) other than clinically failing or
             showing signs of failure on enzalutamide treatment that would require imminent
             discontinuation of enzalutamide treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>370</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>16/03/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Merck Sharp &amp; Dohme - North Ryde</hospital>
    <postcode> - North Ryde</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Espoo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Haar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiyoda-Ku, Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Haarlem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lucerne 6</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hoddesdon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Merck Sharp &amp; Dohme Corp.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a study of pembrolizumab (MK-3475) in participants with metastatic
      castration-resistant prostate cancer (mCRPC). Participants will be enrolled into one of five
      cohorts: Cohort 1 (participants with programmed cell death ligand 1 [PD-L1]-positive,
      measurable disease), Cohort 2 (participants with PD-L1 negative, measurable disease), Cohort
      3 (participants with bone-metastases and non-measurable disease) post-chemotherapy, Cohort 4
      (participants with Response Evaluation Criteria in Solid Tumors version 1.1- [RECIST
      1.1]-measureable disease) and Cohort 5 (participants with bone metastases only or
      bone-predominant disease) pre-chemotherapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02787005</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Merck Sharp &amp; Dohme Corp.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Toll Free Number</name>
      <address />
      <phone>1-888-577-8839</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>